Efficacy and safety of apatinib monotherapy for patients with advanced breast cancer: a systematic review and meta-analysis

ABSTRACT:

Background

Patients with advanced breast cancer usually have poor prognosis. Apatinib is a small-molecule tyrosine kinase inhibitor, and the reports regarding the efficacy and safety of apatinib monotherapy for advanced breast cancer in the current literature are controversial. Therefore, we performed a systematic review and meta-analysis to collect and pool efficacy and safety data of apatinib monotherapy for advanced breast cancer with the aim of providing up-to-date evidence to aid clinical practice.

Methods

This study was registered at PROSPERO (CRD42020190049). Three literature databases, including PubMed, EMBASE, and Cochrane Library, were searched. For evaluating efficacy, the objective response rate and disease control rate were extracted or calculated. Safety was

SUBMITTER: Huang X 

PROVIDER: S-EPMC9376484 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature